Cardinal Health Canada, Futuremed report on proposed acquisition

NewsGuard 100/100 Score

Futuremed Healthcare Products Corporation ("Futuremed") (TSX: FMD) and Cardinal Health Canada Inc. ("Cardinal Health Canada"), a wholly-owned subsidiary of Cardinal Health, Inc. (NYSE: CAH), reported on developments in the Competition Bureau's review of Cardinal Health Canada's proposed acquisition of Futuremed under the Canadian Competition Act.

Cardinal Health Canada and Futuremed filed pre-merger notification filings with the Competition Bureau in respect of the proposed acquisition, and recently received Supplemental Information Requests for additional information required by the Competition Bureau to complete its review of the proposed acquisition. The Supplemental Information Requests were not unexpected and Futuremed and Cardinal Health Canada will continue to work with the Competition Bureau through its ongoing review.

Cardinal Health Canada's offer remains subject to the satisfaction of the conditions detailed in its offer, including a minimum of 66 2/3% of the outstanding common shares of Futuremed being deposited to the offer and regulatory approval under the Competition Act. Further details of Cardinal Health Canada's offer are available in its offer and circular and in Futuremed's directors' circular, each dated November 14, 2011, which have been sent to Futuremed's shareholders and filed on SEDAR at www.sedar.com.

Source:

Cardinal Health Canada Inc.; Futuremed Healthcare Products Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI in healthcare shows promise in trials but needs real-world testing to ensure effectiveness